Renal Denervation
33 places
Worldwide report
Every place
- 33Reports naming them
- 1Markets they lead in
- 33Regions & countries
- 6Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Recor Medical (Otsuka) or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Where they show up
33 reportsOur reports that name Recor Medical (Otsuka) as a key player, by category and place.
- Medical Devices · 33
Places 33
- Africa 1
- APAC 1
- Australia 1
- Brazil 1
- Canada 1
- China 1
- Ecuador 1
- Egypt 1
- Europe 1
France 1- Germany 1
- Global 1
Hong Kong 1
India 1
Italy 1
Japan 1
Kenya 1- Latin America 1
Malaysia 1
Mexico 1- Middle East 1
New Zealand 1- North America 1
Philippines 1
Russia 1
Saudi Arabia 1
Singapore 1
South Africa 1
Spain 1
Thailand 1- UAE 1
UK 1
US 1
Recor Medical (Otsuka)'s markets
1Markets where they are a key player. Each opens the market's statistics for every place we cover.
Medical Devices1
None of their markets match.
Recent reports naming Recor Medical (Otsuka)
Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.
33 places
Companies they compete with most
Named as key players in the same markets as Recor Medical (Otsuka) (number of shared markets).
Ablative Solutions1 shared market
Boston Scientific Corporation1 shared market
Medtronic1 shared market
SoniVie1 shared market
Boston Scientific Corporation1 shared market
Medtronic1 shared market
SoniVie1 shared market
Free public data on Recor Medical (Otsuka)
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Clinical trials
6 active studies led by Recor Medical (Otsuka), of 8 in all
Source: ClinicalTrials.gov, Studies with Recor Medical (Otsuka) (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
US device clearances
1 510(k) clearances and PMA approvals since 2015
- Paradise® Ultrasound Renal Denervation System Ablation Catheter, Renal Denervat… P220023 · 13 Aug 2026
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
Trials over time
Studies Recor Medical (Otsuka) leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Recor Medical (Otsuka) or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Also active in
Markets we cover where free public records show Recor Medical (Otsuka): trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Recor Medical (Otsuka) is in.
From our blog
Stories on the topics Recor Medical (Otsuka) works in.
Omega-3: Heart, Brain and the Evidence Debate
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Breast Cancer Screening and Diagnosis: Closing the Gap
Breast cancer is the most common cancer in women worldwide. Finding it early saves lives, but access to…
Read